ep ahead consensu adj ep
exceed estim stronger revenu profit
factor line ad revis ep guidanc
reflect beat tax reform
lower share base partial off-set china divestitur slower
growth cordi consequ rais ep
tp move higher view
revenu profit exceed plan revenu nice ahead
forecast stronger vs estimate
medic vs segment oper profit growth
pharma well ahead plan partial off-set slightli
weaker medic profit growth vs estimate reflect
pr acquisit ebitda margin increas bp
bp plan gener million cash
facilit deal spend capit expenditur dividend
pre-cal viewshar may edg higher expect undoubtedli
low view share rise latest ep upsid
respect guidanc impli better underli assumpt
core segment exclud china drug price
expect unchang view encourag continu face
pressur suppli commod standpoint exam glove
repres undisclos meaning portion medic unit
contribut temper segment growth flat-down year
expect alreadi
preannounc industri constitu share current
trade ebitda industri peer
view unwarr focu turn execut across recent
acquisit remain posit dispos toward stock
risk includ unfavor drug price trend difficulti integr
valuat metric
number share
price month
 close
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
healthcar servic product compani
distribut brand gener pharmaceut well broad
varieti medic surgic product
better fundament perform sentiment could drive upsid
target price blue sky scenario
weaker fundament perform sentiment could lead
downsid versu target price grey sky scenario
price feb rate outperform target price analyst erin wright
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
cash-flow financ activ
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
 close
compani mention price
